Exovita Biosciences holds the option to an exclusive, worldwide license for the patent-pending technology developed by Kristina Antonia Trujillo, a research assistant professor in UNM’s Department of Biochemistry and Molecular Biology.
In February, Exovita executed a Sponsored Research Agreement with UNM which will see funding for the development of the exosome-based technology as a therapeutic, while the NIH grant will fund the mechanistic investigation of how the exosomes exert their anti-cancer properties.
According to the company, the data generated through these awards will be the foundation for eventual cancer-fighting therapeutics.
Health Sciences Center executive vice chancellor and vice chancellor for research Richard Larson said the NIH grant validates the significant potential of exosome-based cancer therapeutics.
"Exosomes are small, fluid-filled packets that allow our cells to communicate with each other.
"The therapeutic approach being taken by Exovita and Dr Trujillo represents a new way of using our own natural biological process to fight cancer."
Dr Trujillo, the principal investigator for the NIH RO1 grant, has identified specific cells that produce exosomes, which kill cancer cells without harming healthy cells.